Bio-Techne Corp
NASDAQ:TECH
Bio-Techne Corp
Net Issuance of Common Stock
Bio-Techne Corp
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bio-Techne Corp
NASDAQ:TECH
|
Net Issuance of Common Stock
-$107.2m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
-174%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Net Issuance of Common Stock
-$3B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-23%
|
|
|
Danaher Corp
NYSE:DHR
|
Net Issuance of Common Stock
-$6.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Net Issuance of Common Stock
-$832.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-29%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Net Issuance of Common Stock
-$1.8B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-17%
|
|
Bio-Techne Corp
Glance View
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
See Also
What is Bio-Techne Corp's Net Issuance of Common Stock?
Net Issuance of Common Stock
-107.2m
USD
Based on the financial report for Mar 31, 2025, Bio-Techne Corp's Net Issuance of Common Stock amounts to -107.2m USD.
What is Bio-Techne Corp's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-174%
Over the last year, the Net Issuance of Common Stock growth was -220%. The average annual Net Issuance of Common Stock growth rates for Bio-Techne Corp have been -65% over the past three years , -174% over the past five years .
You don't have any saved screeners yet